Novavax Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Novavax (NVAX) Announces 'Going Concern' Qualification
February 28, 2023 4:06 PM ESTNovavax (NASDAQ: NVAX) announced:
Financial Framework
In 2023, Novavax intends to focus the organization to align our investments and activities with our top priority of delivering an updated Covid-19 vaccine consistent with public health recommendations for strain composition for the 2023 fall vaccination season. To... More
Novavax (NVAX) Misses Q4 EPS by $1.09
February 28, 2023 4:03 PM ESTNovavax (NASDAQ: NVAX) reported Q4 EPS of ($2.28), $1.09 worse than the analyst estimate of ($1.19). Revenue for the quarter came in at $357 million versus the consensus estimate of $383.14 million.
For earnings history and earnings-related data on Novavax (NVAX) click here.
... More